MedTrace Logo

A Study to Evaluate the Impact of 11-month Ticagrelor Monotherapy Following One-month DAPT After PCI

NCT05015699 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2024-04-25

No results posted yet for this study

Summary

PIONEER IV CHINA is sought to investigate the safety and efficacy of 11-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after HT Supreme drug-eluting stent system at 12 months follow-up.

Conditions

Interventions

DEVICE

HT Supreme

HT Supreme ( R\&D by Sinomed, Tianjin, China)

Sponsors & Collaborators

  • The Second Affiliated Hospital of Harbin Medical University

    collaborator OTHER

  • Sino Medical Sciences Technology Inc.

    lead INDUSTRY

Principal Investigators

  • Bo Yu, PH.D · The Second Affiliated Hospital of Harbin Medical University

  • Haibo Jia, PH.D · The Second Affiliated Hospital of Harbin Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2022-09-30
Completion
2025-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05015699 on ClinicalTrials.gov